Interstrand Crosslink Repair as a Target for HDAC Inhibition

Trends in Pharmacological Sciences

Volumn 38, Issue 9, 2017, Pages 822-836

  Nikolova, Teodora ^a   Kiweler, Nicole ^a   Krämer, Oliver H ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

chloroethylnitrosoureas; DNA double strand breaks; HDAC; homologous recombination; interstrand crosslink repair; platinum compounds

Indexed keywords

BRCA1 PROTEIN; CISPLATIN; FANCONI ANEMIA PROTEIN; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; MITOMYCIN; PHENYLBUTYRATE; SIRTUIN 1; UNCLASSIFIED DRUG; VORINOSTAT; XERODERMA PIGMENTOSUM GROUP A PROTEIN; INTERCALATING AGENT;

APOPTOSIS; CANCER THERAPY; CHROMOSOMAL INSTABILITY; CYTOTOXICITY; DNA CROSS LINKING; DNA DAMAGE; DNA DAMAGE CHECKPOINT; DNA END JOINING REPAIR; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; EXCISION REPAIR; FANCONI ANEMIA; HOMOLOGOUS RECOMBINATION; HUMAN; MALIGNANT NEOPLASM; PRIORITY JOURNAL; PROTEIN ACETYLATION; PROTEIN FUNCTION; REVIEW; ANIMAL; METABOLISM;

ANIMALS; DNA BREAKS, DOUBLE-STRANDED; DNA DAMAGE; DNA REPAIR; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; INTERCALATING AGENTS;

EID: 85021714834     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2017.05.009     Document Type: Review

References (102)

1. Deans, A.J., West, S.C., DNA interstrand crosslink repair and cancer. Nat. Rev. Cancer 11 (2011), 467–480.
2. Nikolova, T., et al. Chloroethylating nitrosoureas in cancer therapy: DNA damage, repair and cell death signaling. Biochim. Biophys. Acta 1868 (2017), 29–39.
3. Kelley, M.R., et al. Targeting DNA repair pathways for cancer treatment: what's new?. Future Oncol. 10 (2014), 1215–1237.
4. Li, S., Implication of posttranslational histone modifications in nucleotide excision repair. Int. J. Mol. Sci. 13 (2012), 12461–12486.
5. Roos, W.P., Krumm, A., The multifaceted influence of histone deacetylases on DNA damage signalling and DNA repair. Nucleic Acids Res. 44 (2016), 10017–10030.
6. Krämer, O.H., HDAC2: a critical factor in health and disease. Trends Pharmacol. Sci. 30 (2009), 647–655.
7. Wagner, T., et al. Histone deacetylase 2 controls p53 and is a critical factor in tumorigenesis. Biochim. Biophys. Acta 1846 (2014), 524–538.
8. Krämer, O.H., et al. Drugging the HDAC6–HSP90 interplay in malignant cells. Trends Pharmacol. Sci. 35 (2014), 501–509.
9. Cornago, M., et al. Histone deacetylase inhibitors promote glioma cell death by G2 checkpoint abrogation leading to mitotic catastrophe. Cell. Death. Dis., 5, 2014, e1435.
10. Conti, C., et al. Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage. Cancer Res. 70 (2010), 4470–4480.
11. Wells, C.E., et al. Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma. PLoS One, 8, 2013, e68915.
12. Noack, K., et al. Analysis of the interplay between all-trans retinoic acid and histone deacetylase inhibitors in leukemic cells. Arch. Toxicol. 91 (2017), 2191–2208.
13. Vogelauer, M., et al. Histone acetylation regulates the time of replication origin firing. Mol. Cell. 10 (2002), 1223–1233.
14. Li, Z., Zhu, W.G., Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications. Int. J. Biol. Sci. 10 (2014), 757–770.
15. Hashimoto, S., et al. Mechanisms of interstrand DNA crosslink repair and human disorders. Genes Environ., 38, 2016, 9.
16. Schärer, O.D., DNA interstrand crosslinks: natural and drug-induced DNA adducts that induce unique cellular responses. Chembiochem 6 (2005), 27–32.
17. Michl, J., et al. Interplay between Fanconi anemia and homologous recombination pathways in genome integrity. EMBO J. 35 (2016), 909–923.
18. Noll, D.M., et al. Formation and repair of interstrand crosslinks in DNA. Chem. Rev. 106 (2006), 277–301.
19. Sengerova, B., et al. Orchestrating the nucleases involved in DNA interstrand crosslink (ICL) repair. Cell Cycle 10 (2011), 3999–4008.
20. Barrientos, J.C., Management of chronic lymphocytic leukemia in the elderly. Cancer Control 22 (2015), 17–23.
21. Mauro, F.R., et al. Management of elderly and unfit patients with chronic lymphocytic leukemia. Expert Rev. Hematol. 9 (2016), 1165–1175.
22. Landgren, O., Owen, R.G., Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient. Cytometry B Clin. Cytometry 90 (2016), 14–20.
23. Mobus, V., Adjuvant dose-dense chemotherapy in breast cancer: standard of care in high-risk patients. Breast Care 11 (2016), 8–12.
24. Barber, E.L., et al. The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer. J. Gynecol. Oncol. 24 (2013), 258–264.
25. Bryan, R.T., Optimising existing therapeutic strategies for the treatment of non-muscle-invasive bladder cancer: the role of intensive neoadjuvant intravesical mitomycin C. Eur. Urol. 62 (2012), 803–805.
26. Ospovat, I., et al. Mitomycin C and vinblastine: an active regimen in previously treated breast cancer patients. Tumori 95 (2009), 683–686.
27. Pothiawala, S.Z., et al. The role of phototherapy in cutaneous T-cell lymphoma. J. Drugs Dermatol. 9 (2010), 764–772.
28. Ceccaldi, R., et al. The Fanconi anaemia pathway: new players and new functions. Nat. Rev. Mol. Cell Biol. 17 (2016), 337–349.
29. Sawyer, S.L., et al. Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype. Cancer Discovery 5 (2015), 135–142.
30. Lopez-Martinez, D., et al. Cellular response to DNA interstrand crosslinks: the Fanconi anemia pathway. Cell Mol. Life Sci. 73 (2016), 3097–3114.
31. Xue, X., et al. Functions and regulation of the multitasking FANCM family of DNA motor proteins. Genes. Dev. 29 (2015), 1777–1788.
32. Gibbs-Seymour, I., et al. Ubiquitin-SUMO circuitry controls activated fanconi anemia ID complex dosage in response to DNA damage. Mol. Cell. 57 (2015), 150–164.
33. Quiros, S., et al. Rad51 and BRCA2 – new molecular targets for sensitizing glioma cells to alkylating anticancer drugs. PLoS One, 6, 2011, e27183.
34. Nikolova, T., et al. Chloroethylnitrosourea-induced cell death and genotoxicity: cell cycle dependence and the role of DNA double-strand breaks, HR and NHEJ. Cell Cycle 11 (2012), 2606–2619.
35. Kondo, N., et al. FANCD1/BRCA2 plays predominant role in the repair of DNA damage induced by ACNU or TMZ. PLoS One, 6, 2011, e19659.
36. Hartman, A.R., Ford, J.M., BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair. Nat. Genet. 32 (2002), 180–184.
37. Long, D.T., et al. BRCA1 promotes unloading of the CMG helicase from a stalled DNA replication fork. Mol. Cell. 56 (2014), 174–185.
38. Bunting, S.F., Nussenzweig, A., Dangerous liaisons: Fanconi anemia and toxic nonhomologous end joining in DNA crosslink repair. Mol. Cell. 39 (2010), 164–166.
39. Bunting, S.F., et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 141 (2010), 243–254.
40. Burkitt, K., Ljungman, M., Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin. Mol. Cancer, 7, 2008, 24.
41. Konstantinopoulos, P.A., et al. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer. Gynecol. Oncol. 133 (2014), 599–606.
42. Witzig, T.E., et al. Induction of apoptosis in malignant B cells by phenylbutyrate or phenylacetate in combination with chemotherapeutic agents. Clin. Cancer Res. 6 (2000), 681–692.
43. Krumm, A., et al. Enhanced histone deacetylase activity in malignant melanoma provokes RAD51 and FANCD2-triggered drug resistance. Cancer Res. 76 (2016), 3067–3077.
44. Rjiba-Touati, K., et al. Role of recombinant human erythropoietin against mitomycin C-induced cardiac, hepatic and renal dysfunction in Wistar rats. Human Exp. Toxicol. 34 (2015), 468–478.
45. Marosi, C., Complications of chemotherapy in neuro-oncology. Handb Clin. Neurol. 105 (2012), 873–885.
46. Belo, H., et al. Epigenetic alterations in Fanconi anaemia: role in pathophysiology and therapeutic potential. PLoS One, 10, 2015, e0139740.
47. Guervilly, J.H., et al. Loss of CHK1 function impedes DNA damage-induced FANCD2 monoubiquitination but normalizes the abnormal G2 arrest in Fanconi anemia. Hum. Mol. Genet. 17 (2008), 679–689.
48. Fuss, J.O., Tainer, J.A., XPB and XPD helicases in TFIIH orchestrate DNA duplex opening and damage verification to coordinate repair with transcription and cell cycle via CAK kinase. DNA Repair 10 (2011), 697–713.
49. Yokoi, M., Hanaoka, F., Two mammalian homologs of yeast Rad23, HR23A and HR23B, as multifunctional proteins. Gene 597 (2017), 1–9.
50. Vlachostergios, P.J., et al. The ubiquitin-proteasome system in cancer, a major player in DNA repair: Part 1: post-translational regulation. J. Cell Mol. Med. 13 (2009), 3006–3018.
51. Barckhausen, C., et al. Malignant melanoma cells acquire resistance to DNA interstrand crosslinking chemotherapeutics by p53-triggered upregulation of DDB2/XPC-mediated DNA repair. Oncogene 33 (2014), 1964–1974.
52. Batista, L.F., et al. Differential sensitivity of malignant glioma cells to methylating and chloroethylating anticancer drugs: p53 determines the switch by regulating xpc, ddb2, and DNA double-strand breaks. Cancer Res. 67 (2007), 11886–11895.
53. Beli, P., et al. Proteomic investigations reveal a role for RNA processing factor THRAP3 in the DNA damage response. Mol. Cell. 46 (2012), 212–225.
54. Choudhary, C., et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325 (2009), 834–840.
55. Elia, A.E., et al. Quantitative proteomic atlas of ubiquitination and acetylation in the DNA damage response. Mol. Cell. 59 (2015), 867–881.
56. Angelika Ihle, M., et al. HR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostat. J. Pathol. Clin. Res. 2 (2016), 59–71.
57. Khan, O., et al. HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 6532–6537.
58. New, M., et al. A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors. Cell. Death. Differ. 20 (2013), 1306–1316.
59. Hurwitz, J.L., et al. Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent. Eur. J. Cancer 48 (2012), 1096–1107.
60. Choi, J.Y., et al. Enhanced nucleotide excision repair capacity in lung cancer cells by preconditioning with DNA-damaging agents. Oncotarget 6 (2015), 22575–22586.
61. Ming, M., et al. Dual role of SIRT1 in UVB-induced skin tumorigenesis. Oncogene 34 (2015), 357–363.
62. Fan, W., Luo, J., SIRT1 regulates UV-induced DNA repair through deacetylating XPA. Mol. Cell. 39 (2010), 247–258.
63. Sakao, Y., et al. Cisplatin induces Sirt1 in association with histone deacetylation and increased Werner syndrome protein in the kidney. Clin. Exp. Nephrol. 15 (2011), 363–372.
64. Kang, T.H., et al. Regulation of nucleotide excision repair activity by transcriptional and post-transcriptional control of the XPA protein. Nucleic Acids Res. 39 (2011), 3176–3187.
65. Zhang, T., et al. SIRT1 expression is associated with the chemotherapy response and prognosis of patients with advanced NSCLC. PLoS One, 8, 2013, e79162.
66. Rafehi, H., et al. Pharmacological histone deacetylation segregates distinct transcriptional regulators. Curr. Top. Med. Chem. 17 (2017), 1611–1622.
67. Huang, Y., et al. EZH2 suppresses the nucleotide excision repair in nasopharyngeal carcinoma by silencing XPA gene. Mol. Carcinog. 56 (2017), 447–463.
68. Chiba, N., Parvin, J.D., The BRCA1 and BARD1 association with the RNA polymerase II holoenzyme. Cancer Res. 62 (2002), 4222–4228.
69. Gong, C., et al. BRCA1 positively regulates FOXO3 expression by restricting FOXO3 gene methylation and epigenetic silencing through targeting EZH2 in breast cancer. Oncogenesis, 5, 2016, e214.
70. Li, T., et al. EZH2 participates in malignant biological behavior of epithelial ovarian cancer through regulating the expression of BRCA1. Cancer. Biol. Ther. 15 (2014), 271–278.
71. Wang, L., et al. BRCA1 is a negative modulator of the PRC2 complex. EMBO J. 32 (2013), 1584–1597.
72. Stecklein, S.R., et al. BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 13650–13655.
73. Fujii, N., et al. A novel assay revealed that ribonucleotide reductase is functionally important for interstrand DNA crosslink repair. Bioorgan. Med. Chem. 23 (2015), 6912–6921.
74. Tillhon, M., et al. p300/CBP acetyl transferases interact with and acetylate the nucleotide excision repair factor XPG. DNA Repair 11 (2012), 844–852.
75. Cai, Y., et al. The predictive value of ERCC1 and p53 for the effect of panobinostat and cisplatin combination treatment in NSCLC. Oncotarget 6 (2015), 18997–19005.
76. Bowden, N.A., Nucleotide excision repair: why is it not used to predict response to platinum-based chemotherapy?. Cancer Lett. 346 (2014), 163–171.
77. Enoiu, M., et al. Repair of cisplatin-induced DNA interstrand crosslinks by a replication-independent pathway involving transcription-coupled repair and translesion synthesis. Nucleic Acids Res. 40 (2012), 8953–8964.
78. Iyama, T., et al. CSB interacts with SNM1A and promotes DNA interstrand crosslink processing. Nucleic Acids Res. 43 (2015), 247–258.
79. Wang, Y., et al. Ultraviolet-B induces ERCC6 repression in lens epithelium cells of age-related nuclear cataract through coordinated DNA hypermethylation and histone deacetylation. Clin. Epigenet., 8, 2016, 62.
80. Robert, T., et al. HDACs link the DNA damage response, processing of double-strand breaks and autophagy. Nature 471 (2011), 74–79.
81. Kaidi, A., et al. Human SIRT6 promotes DNA end resection through CtIP deacetylation. Science 329 (2010), 1348–1353.
82. Duquette, M.L., et al. CtIP is required to initiate replication-dependent interstrand crosslink repair. PLoS Genet., 8, 2012, e1003050.
83. Hassa, P.O., et al. Acetylation of poly(ADP-ribose) polymerase-1 by p300/CREB-binding protein regulates coactivation of NF-kappaB-dependent transcription. J. Biol. Chem. 280 (2005), 40450–40464.
84. Lagunas, V.M., Melendez-Zajgla, J., Nuclear factor-kappa B as a resistance factor to platinum-based antineoplasic drugs. Metal-based Drugs, 2008, 2008, 576104.
85. Cui, X., et al. The XRCC2 and XRCC3 repair genes are required for chromosome stability in mammalian cells. Mutat. Res. 434 (1999), 75–88.
86. Clingen, P.H., et al. Histone H2AX phosphorylation as a molecular pharmacological marker for DNA interstrand crosslink cancer chemotherapy. Biochem. Pharmacol. 76 (2008), 19–27.
87. Berte, N., et al. Targeting homologous recombination by pharmacological inhibitors enhances the killing response of glioblastoma cells treated with alkylating drugs. Mol. Cancer Ther. 15 (2016), 2665–2678.
88. Ito, M., et al. Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin. J. Gene Med. 7 (2005), 1044–1052.
89. Uhl, M., et al. Role of SIRT1 in homologous recombination. DNA Repair 9 (2010), 383–393.
90. Adimoolam, S., et al. HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 19482–19487.
91. Groselj, B., et al. Radiosensitisation of bladder cancer cells by panobinostat is modulated by Ku80 expression. Radiother. Oncol. 108 (2013), 429–433.
92. Chun, S.G., et al. Targeted inhibition of histone deacetylases and hedgehog signaling suppress tumor growth and homologous recombination in aerodigestive cancers. Am. J. Cancer. Res. 5 (2015), 1337–1352.
93. Kotian, S., et al. Histone deacetylases 9 and 10 are required for homologous recombination. J. Biol. Chem. 286 (2011), 7722–7726.
94. Fukuda, T., et al. Class I histone deacetylase inhibitors inhibit the retention of BRCA1 and 53BP1 at the site of DNA damage. Cancer Sci. 106 (2015), 1050–1056.
95. Smith, S., et al. Histone deacetylase inhibitors selectively target homology dependent DNA repair defective cells and elevate non-homologous endjoining activity. PLoS One, 9, 2014, e87203.
96. Kuo, C.Y., et al. Repairing of N-mustard derivative BO-1055 induced DNA damage requires NER, HR, and MGMT-dependent DNA repair mechanisms. Oncotarget 6 (2015), 25770–25783.
97. Thurn, K.T., et al. Histone deacetylase regulation of ATM-mediated DNA damage signaling. Mol. Cancer Ther. 12 (2013), 2078–2087.
98. Sun, Y., et al. DNA damage-induced acetylation of lysine 3016 of ATM activates ATM kinase activity. Mol. Cell Biol. 27 (2007), 8502–8509.
99. Hovest, M.G., et al. Differential roles for Chk1 and FANCD2 in ATR-mediated signalling for psoralen photoactivation-induced senescence. Exp. Dermatol. 20 (2011), 883–889.
100. Jiang, Y., et al. Sirtuin inhibition: strategies, inhibitors, and therapeutic potential. Trends Pharmacol. Sci. 38 (2017), 459–472.
101. Beier, U.H., et al. Histone/protein deacetylases control Foxp3 expression and the heat shock response of T-regulatory cells. Curr. Opin. Immunol. 23 (2011), 670–678.
102. + regulatory T cell function through shared and isoform-specific mechanisms. Sci. Signal., 5, 2012, ra45.